药物名称：冻干 b 型流感嗜血杆菌结合疫苗； 证券代码：300318 证券简称：博晖创新 公告编号：临 2025-036 北京博晖创新生物技术集团股份有限公司 关于控股孙公司联合获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京博晖创新生物技术集团股份有限公司（以下简称"公司"）控股 孙公司博晖生物制药股份有限公司（以下简称"廊坊博晖"）与北京百晖生物科 技有限公司（以下简称"百晖生物"）联合申报的冻干 b 型流感嗜血杆菌结合疫 苗，获得国家药品监督管理局出具的《药物临床试验批准通知书》，同意开展临 床试验。具体情况如下： 一、基本情况 受理号：CXSL2500616； 通知书编号：2025LP02755； 药品类型：预防用生物制品； 注册分类：3.3； 申请人：博晖生物制药股份有限公司、北京百晖生物科技有限公司； 适应症：本疫苗接种后，可使机体产生体液免疫应答。用于预防由 b 型流感 嗜血杆菌引起的侵袭性感染（包括脑膜炎、肺炎、败血症、蜂窝组织炎、关节炎、 会厌炎等）。 二、其他相关情况 廊坊博晖与百晖生物联合申报的 ...

Core Viewpoint - The company announced that its subsidiary, Bohui Biopharmaceutical Co., Ltd., in collaboration with Beijing Baihui Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of a lyophilized type B Haemophilus influenzae conjugate vaccine [1] Group 1 - The clinical trial approval indicates progress in the development of the vaccine, which may enhance the company's product portfolio in the biopharmaceutical sector [1] - The collaboration with Beijing Baihui Biotechnology Co., Ltd. suggests a strategic partnership aimed at leveraging combined expertise for vaccine development [1]

Core Viewpoint - The report highlights the increasing accounts receivable among A-share pharmaceutical companies, with a significant number exceeding 10 billion yuan, indicating potential liquidity issues and financial health concerns in the industry [1][3]. Accounts Receivable Overview - As of the end of Q3, 14 A-share pharmaceutical companies reported accounts receivable exceeding 10 billion yuan, with Shanghai Pharmaceuticals leading at 88.783 billion yuan, followed by Jiuzhoutong at 39.09 billion yuan [3][4]. - The blood products sector has seen a notable increase in accounts receivable, with companies like Tiantan Biological and Boya Biological reporting significant year-on-year growth [5][6]. Industry Characteristics - The pharmaceutical distribution sector is primarily responsible for high accounts receivable, as public hospitals, which dominate the market, often negotiate longer payment terms, leading to increased receivables for distributors [3][10]. - Companies may adopt lenient credit policies to attract more clients, which can temporarily boost sales but also result in higher accounts receivable [3][10]. Financial Ratios - Eight companies have accounts receivable constituting over 50% of their total assets, with Renmin Tongtai having the highest ratio at 62.1% [8][9]. - *ST Suwu and Zhongyao Holdings follow, with accounts receivable ratios of 56.28% and significant increases compared to the previous year [9][10]. Performance Implications - High accounts receivable can lead to reduced cash flow and increased opportunity costs, potentially impacting profitability due to higher bad debt provisions [10]. - However, in certain scenarios, elevated accounts receivable may not be detrimental if they align with healthy revenue and profit growth, and if customer quality and payment terms are managed effectively [10].

Core Viewpoint - 博晖创新 is a key player in the clinical testing and blood products sector in China, with a focus on rapid testing technology development and application [1] Group 1: Business Overview - 博晖创新 was established on July 12, 2001, and listed on the Shenzhen Stock Exchange on May 23, 2012, with its headquarters in Beijing [1] - The company's main business includes the research, development, production, and sales of clinical testing rapid detection technology and blood products [1] - The company operates in the pharmaceutical and biological industry, specifically in the blood products sector, covering concepts such as anti-influenza, hepatitis treatment, and monkeypox [1] Group 2: Financial Performance - In Q3 2025, 博晖创新 achieved a revenue of 629 million yuan, ranking 6th among 7 companies in the industry [2] - The industry leader, 上海莱士, reported a revenue of 6.091 billion yuan, while the second-ranked 天坛生物 had a revenue of 4.465 billion yuan [2] - The average revenue in the industry was 2.155 billion yuan, with a median of 1.474 billion yuan [2] - The company's net profit for the same period was -61.46 million yuan, also ranking 6th in the industry [2] - The industry leader's net profit was 1.47 billion yuan, and the second-ranked company reported 1.12 billion yuan [2] - The average net profit in the industry was 466.7 million yuan, with a median of 343 million yuan [2] Group 3: Financial Ratios - As of Q3 2025, 博晖创新's debt-to-asset ratio was 47.10%, higher than the previous year's 42.03% and above the industry average of 28.01% [3] - The gross profit margin for the same period was 39.33%, down from 50.65% in the previous year and below the industry average of 44.76% [3] Group 4: Executive Compensation - The chairman, 沈治卫, received a salary of 1.8047 million yuan in 2024, an increase of 209,300 yuan from 2023 [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for 博晖创新 was 28,200, a decrease of 9.42% from the previous period [5] - The average number of circulating A-shares held per shareholder increased by 10.40% to 28,300 [5] - Among the top ten circulating shareholders, 香港中央结算有限公司 ranked as the ninth largest, holding 4.0538 million shares, a decrease of 27,200 shares from the previous period [5]

Core Viewpoint - 博晖创新 reported a decline in revenue and a net loss for the first three quarters of 2025, indicating financial challenges faced by the company [1] Financial Performance - The company's revenue for the first three quarters was 629 million yuan, representing a year-on-year decrease of 2.68% [1] - The net loss attributable to shareholders was 33.6152 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 18.73 million yuan [1] - The basic loss per share was 0.0411 yuan [1]

Core Insights - The company reported a revenue of 629 million yuan for the first three quarters of 2025, representing a year-on-year decline of 2.68% [1] - The net profit attributable to the parent company was -33.6152 million yuan, a significant year-on-year decrease of 241.73% [1] - In the third quarter of 2025, the company achieved a single-quarter main business revenue of 225 million yuan, showing a year-on-year increase of 41.22% [1] Financial Performance - Total assets reached 4.326 billion yuan, reflecting a growth of 4.85% compared to the end of the previous year [1] - The company continues to focus on research and application in biotechnology, aiming to provide innovative biological solutions to customers [1] Business Strategy - The company is actively working on sales and marketing efforts to enhance its product market share [1]

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-034 北京博晖创新生物技术集团股份有限公司 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第十三次会议于 2025 年 10 月 29 日在公司会议室召开，会议通知于 2025 年 10 月 17 日以专人送达、邮件通知或电话通知的方式送达各位监事。会议 由公司监事会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本 次会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集召开程序符合《公司 法》和《公司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《2025 年第三季度报告》 监事会认为：公司结合 2025 年第三季度的实际经营管理情况编制的《2025 年 第三季度报告》符合《深圳证券交易所创业板股票上市规则》、《上市公司信息披露 管理办法》等法律法规的相关要求。其内容真实、准确、完整的反映了公司 2025 年第三季度的经营管理情况，不存在虚假记载、误导性陈述或重大遗漏。该报告未 经会计师事务所审计。 具体内容详见公司于同日在巨潮资讯网（www. ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-033 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第十四次会议于 2025 年 10 月 29 日在公司会议室召开，会议通知 于 2025 年 10 月 17 日以专人送达、邮件通知或电话通知的方式送达各位董事， 会议由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行， 本次会议应出席董事 7 人，实际出席董事 7 人，监事列席了会议。本次会议的召 集召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《2025 年第三季度报告》 同意公司根据《深圳证券交易所创业板股票上市规则》等法律法规的相关要 求，结合本公司 2025 年第三季度的实际经营管理情况编制《2025 年第三季度报 告》。该报告未经会计师事务所审计。 具体内容详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的《2025 年第三季度报告》。 公司《2025 年第三季度报告》财务报告部分已经公司第八届董事会审计委 员会 2025 年第四次会议审 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥224,795,115.32, representing a 41.22% increase compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥14,926,965.32, a decline of 281.18% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥866,968.99, an increase of 108.12% compared to the previous year[5] - Total operating revenue for the current period is ¥628,755,157.52, a decrease from ¥646,068,014.18 in the previous period[22] - The net profit for the current period is a loss of ¥61,457,144.57, compared to a profit of ¥45,007,016.93 in the previous period[24] - The total profit for the current period is a loss of ¥57,250,610.96, down from a profit of ¥61,757,634.62 in the previous period[24] - Basic and diluted earnings per share for the current period are both -0.0411, compared to 0.0290 in the previous period[25] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥4,325,604,408.30, reflecting a 4.85% increase from the end of the previous year[5] - The company's total assets amount to 4,325,604,408.30 yuan, an increase from 4,125,558,100.42 yuan at the beginning of the period[19] - Current assets total 1,400,347,746.79 yuan, up from 1,226,324,965.41 yuan at the beginning of the period[18] - The company's total liabilities increased by 85.86% to ¥510,254,394.24, mainly due to increased borrowings from related parties[10] - The company's total liabilities are 2,037,149,708.90 yuan, compared to 1,776,429,561.09 yuan previously[20] - The non-current assets total 2,925,256,661.51 yuan, slightly increasing from 2,899,233,135.01 yuan[19] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥108,747,996.84, a significant decline of 799.57% year-on-year[5] - Cash flow from operating activities shows a net outflow of ¥108,747,996.84, compared to a smaller outflow of ¥12,088,916.80 in the previous period[26] - Cash flow from investing activities resulted in a net outflow of ¥126,134,188.46, compared to a net outflow of ¥150,866,059.82 in the previous period[26] - Cash flow from financing activities generated a net inflow of ¥258,306,054.70, up from ¥176,991,593.07 in the previous period[26] - The ending cash and cash equivalents balance is ¥79,345,728.16, down from ¥97,274,347.95 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,173[15] - The largest shareholder, Du Jiangtao, holds 39.03% of the shares, totaling 318,811,388 shares[15] Other Financial Metrics - The weighted average return on net assets was -1.09%, a decrease of 0.81% compared to the previous year[5] - Accounts receivable increased by 66.09% to ¥97,285,548.01, primarily due to extended payment terms for sales to creditworthy customers[10] - The company reported a 2788.90% increase in other operating expenses, totaling ¥50,314,239.09, mainly due to contract termination compensation payments[12] - Cash received from investment activities was ¥10,152,104.55, a 100% increase compared to the previous year, attributed to the recovery of financial investments[13] - The company's retained earnings show a deficit of -232,898,891.06 yuan, worsening from -199,283,721.15 yuan[20] - Total operating costs increased to ¥636,547,436.97 from ¥602,017,288.79, with operating costs specifically rising to ¥381,441,266.08 from ¥318,826,772.88[23] Audit Status - The financial report for the third quarter has not been audited[28]

Core Viewpoint - The blood products industry is experiencing significant performance differentiation among listed companies due to fluctuating terminal medical demand, ongoing centralized procurement policies, and intensified competition for plasma station resources [1][2]. Revenue Performance - The blood products industry has shown a clear tiered revenue structure, with leading companies benefiting from resource barriers while smaller firms struggle with revenue growth [2][3]. - Shanghai Raist achieved a revenue of 3.952 billion yuan, with a year-on-year plasma collection increase of nearly 12% [2]. - Tian Tan Bio reported a revenue of 3.110 billion yuan, a year-on-year increase of 9.47%, supported by its stable plasma collection capabilities [2]. - Hualan Bio generated a revenue of 1.798 billion yuan, up 8.8% year-on-year, with its blood products segment contributing 1.737 billion yuan, a 7.57% increase [2]. - The top three companies accounted for 74.64% of the total revenue of the eight listed companies in the industry [2]. Profitability Analysis - There is a significant disparity in net profit performance, with only two companies reporting positive year-on-year growth in net profit [4][5]. - Shanghai Raist led with a net profit of 1.03 billion yuan, while Hualan Bio saw a notable increase of 17.19% in net profit to 516 million yuan, driven by improved gross margins [4]. - Tian Tan Bio's net profit decreased by 12.88% to 633 million yuan, impacted by declining product sales prices and reduced interest income [4]. - The profitability of smaller companies is under pressure, with Baiya Bio reporting a net profit of 225 million yuan and a cash dividend plan reflecting shareholder returns [5]. - Bai Lin Bio's net profit fell by 27.89% to 236 million yuan due to capacity expansion efforts, while Wei Guang Bio's net profit slightly decreased by 2.02% to 108 million yuan [5][6]. Industry Challenges - The industry faces challenges such as weak terminal demand, ongoing centralized procurement pressures, and financial and R&D constraints [6]. - The demand for conventional products like human albumin has decreased due to adjustments in treatment rhythms at medical institutions [6]. - Centralized procurement policies continue to exert pressure on pricing, affecting revenue from related business lines [6]. - Companies are experiencing tight funding issues as they invest in expanding plasma stations and advancing new product development [6].